BACKGROUND: Evidence suggests that a raised level of cord serum IgE (CS-IgE) is a risk factor for allergic sensitisation. However, whether CS-IgE is a risk for asthma is controversial. A study was undertaken to investigate the association between CS-IgE levels and allergic sensitisation at 4 and 10 years of age and asthma at ages 1-2, 4 and 10. METHODS: CS-IgE was available for 1358 of 1456 children born between 1989 and 1990. The cohort was evaluated for allergic diseases at ages 1, 2, 4 and 10 years. Skin prick tests for six allergens were performed on 981 children at age 4 and 1036 at age 10. Asthma was defined based on a physician's diagnosis. Using logistic regression analysis, the risk of asthma and allergic sensitisation for raised levels of CS-IgE (> or =0.5 kU/l) was estimated. RESULTS: At ages 4 and 10 years 20.2% and 27.0% of children, respectively, had allergic sensitisation. The risk of allergic sensitisation was significantly associated with raised CS-IgE levels at ages 4 (OR 2.29) and 10 years (OR 1.73). The prevalence of asthma was 10.3% at age 1-2, 15.2% at age 4, and 12.8% at age 10. CS-IgE was not associated with asthma at age 1-2 and 4 but showed an increased relative risk at age 10 (OR 1.66, 95% CI 1.05 to 2.62). The association was stronger in children who did not develop allergic sensitisation at age 4 or 10 (OR 3.35, 95% CI 1.41 to 7.93). CONCLUSIONS: Raised cord serum IgE is a risk factor for allergic sensitisation at ages 4 and 10 years. This is the second study suggesting that CS-IgE is also a risk factor for asthma at age 10, probably related to the late onset of asthma. This association is not necessarily mediated by allergic sensitisation.
BACKGROUND: Evidence suggests that a raised level of cord serum IgE (CS-IgE) is a risk factor for allergic sensitisation. However, whether CS-IgE is a risk for asthma is controversial. A study was undertaken to investigate the association between CS-IgE levels and allergic sensitisation at 4 and 10 years of age and asthma at ages 1-2, 4 and 10. METHODS:CS-IgE was available for 1358 of 1456 children born between 1989 and 1990. The cohort was evaluated for allergic diseases at ages 1, 2, 4 and 10 years. Skin prick tests for six allergens were performed on 981 children at age 4 and 1036 at age 10. Asthma was defined based on a physician's diagnosis. Using logistic regression analysis, the risk of asthma and allergic sensitisation for raised levels of CS-IgE (> or =0.5 kU/l) was estimated. RESULTS: At ages 4 and 10 years 20.2% and 27.0% of children, respectively, had allergic sensitisation. The risk of allergic sensitisation was significantly associated with raised CS-IgE levels at ages 4 (OR 2.29) and 10 years (OR 1.73). The prevalence of asthma was 10.3% at age 1-2, 15.2% at age 4, and 12.8% at age 10. CS-IgE was not associated with asthma at age 1-2 and 4 but showed an increased relative risk at age 10 (OR 1.66, 95% CI 1.05 to 2.62). The association was stronger in children who did not develop allergic sensitisation at age 4 or 10 (OR 3.35, 95% CI 1.41 to 7.93). CONCLUSIONS: Raised cord serum IgE is a risk factor for allergic sensitisation at ages 4 and 10 years. This is the second study suggesting that CS-IgE is also a risk factor for asthma at age 10, probably related to the late onset of asthma. This association is not necessarily mediated by allergic sensitisation.
Authors: J Kuehr; W Karmaus; T Frischer; A Hendel-Kramer; K Weiss; M Moseler; V Stephan; J Forster; R Urbanek Journal: Clin Exp Allergy Date: 1992-09 Impact factor: 5.018
Authors: R L Bergmann; G Edenharter; K E Bergmann; I Guggenmoos-Holzmann; J Forster; C P Bauer; V Wahn; F Zepp; U Wahn Journal: Clin Exp Allergy Date: 1997-07 Impact factor: 5.018
Authors: O Oluwole; O G Arinola; G A Falade; M O Ige; G A Falusi; T Aderemi; D Huo; I O Olopade; C O Olopade Journal: Afr Health Sci Date: 2013-03 Impact factor: 0.927
Authors: S Hasan Arshad; John W Holloway; Wilfried Karmaus; Hongmei Zhang; Susan Ewart; Linda Mansfield; Sharon Matthews; Claire Hodgekiss; Graham Roberts; Ramesh Kurukulaaratchy Journal: Int J Epidemiol Date: 2018-08-01 Impact factor: 7.196
Authors: Purvee S Shah; Ganesa Wegienka; Suzanne Havstad; Christine Cole Johnson; Dennis R Ownby; Edward M Zoratti Journal: Ann Allergy Asthma Immunol Date: 2011-01-26 Impact factor: 6.347
Authors: Hartmut Vogt; Lennart Bråbäck; Olof Zetterström; Katalin Zara; Karin Fälth-Magnusson; Lennart Nilsson Journal: PLoS One Date: 2013-06-21 Impact factor: 3.240